Omeros Corp. (OMER)

Trade OMER now with
3/1/2019 7:37:35 AM Omeros Q4 Net Loss $23.5 Mln Or $0.48/Shr Vs Loss $16.6 Mln Or $0.34/Shr Last Year
2/14/2019 8:35:56 AM Omeros Streamlines Path To BLA For OMS721 In HSCT-TMA Following Meeting With FDA
2/12/2019 8:33:42 AM Omeros Appoints Thomas Bumol To Board
1/17/2019 8:15:44 AM Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy
1/14/2019 7:36:00 AM Omeros Corp Sees Q4 Preliminary Total And OMIDRIA 1%/0.3% Revenues To Be At About $22.0 Mln
12/11/2018 7:30:39 AM Omeros Announces Research Collaboration With University Of Cambridge
11/9/2018 7:05:23 AM Omeros Reports Pricing Of $210 Mln Offering Of Convertible Senior Notes Due 2023
10/23/2018 8:34:55 AM FDA Grants Orphan Drug Designation To Omeros’ OMS721 For HSCT-TMA
10/1/2018 8:48:47 AM Omeros Reports Reinstatement Of Pass-Through Status For OMIDRIA
8/10/2018 5:41:24 PM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $20 Price Target
7/26/2018 7:39:20 AM Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros’ Drug Expire
7/25/2018 8:42:58 AM Omeros’ OMS721 Gets EU Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation
7/23/2018 7:15:51 AM Omeros Corporation Initiates Sales Of OMIDRIA In Europe
7/17/2018 7:03:05 AM Omeros Initiates Dosing In Phase 1 Trial For OMS527 Targeting Addiction
7/17/2018 7:02:18 AM Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction
6/27/2018 9:16:23 AM Omeros Secures Approval To Begin Phase 1 Clinical Trial For Its OMS527 Addiction Treatment